Subscribe
shutterstock_1953872293_marlon_trottmann
Marlon Trottmann / Shutterstock.com
25 November 2021AmericasMuireann Bolger

Fed Circ invaded jury’s role in Repatha case, says Amgen

Amgen has urged the US Supreme Court to wade into its legal wrangle with Sanofi and Regeneron Pharmaceuticals over patents covering a cholesterol drug, Repatha (evolocumab).

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
Amgen asks SCOTUS to reject Roche petition
14 April 2021   Amgen subsidiary Immunex has asked the US Supreme Court not to review a Federal Circuit decision that found the company did not patent the same rheumatoid arthritis invention twice.
Americas
GSK claims Amgen v Sanofi decision “threatens” innovation
29 April 2021   GlaxoSmithKline has submitted an amicus brief to the Court of Appeals for the Federal Circuit claiming that the ruling on Amgen v Sanofi could “threaten incentives to invest in future discoveries.”
Americas
SCOTUS agrees to hear Amgen revival bid
7 November 2022   The dispute centres on a section of the Patent Act concerning 'enablement' | The US government had urged the court to deny the petition.


Editor's picks

Americas
Trump’s return sparks calls for pro-patent agenda
5 December 2024

Editor's picks

Americas
Trump’s return sparks calls for pro-patent agenda
5 December 2024
Americas
Comparing life sciences IP in Brazil and the US
28 November 2024
Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024
Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024
Americas
Big Pharma counsel embrace AI but data and legal risks loom
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024

More on this story

Big Pharma
Amgen asks SCOTUS to reject Roche petition
14 April 2021   Amgen subsidiary Immunex has asked the US Supreme Court not to review a Federal Circuit decision that found the company did not patent the same rheumatoid arthritis invention twice.
Americas
GSK claims Amgen v Sanofi decision “threatens” innovation
29 April 2021   GlaxoSmithKline has submitted an amicus brief to the Court of Appeals for the Federal Circuit claiming that the ruling on Amgen v Sanofi could “threaten incentives to invest in future discoveries.”
Americas
SCOTUS agrees to hear Amgen revival bid
7 November 2022   The dispute centres on a section of the Patent Act concerning 'enablement' | The US government had urged the court to deny the petition.

More on this story

Big Pharma
Amgen asks SCOTUS to reject Roche petition
14 April 2021   Amgen subsidiary Immunex has asked the US Supreme Court not to review a Federal Circuit decision that found the company did not patent the same rheumatoid arthritis invention twice.
Americas
GSK claims Amgen v Sanofi decision “threatens” innovation
29 April 2021   GlaxoSmithKline has submitted an amicus brief to the Court of Appeals for the Federal Circuit claiming that the ruling on Amgen v Sanofi could “threaten incentives to invest in future discoveries.”
Americas
SCOTUS agrees to hear Amgen revival bid
7 November 2022   The dispute centres on a section of the Patent Act concerning 'enablement' | The US government had urged the court to deny the petition.

More features

Fed Circ orders Teva to delist five patents from Orange Book
Sarepta wins $115M in patent dispute over muscular dystrophy drug
Novartis shields eye-drop patent at European Patent Office
CREATES Act unfairly tips the scales to generics
LSPN launches its first-ever US awards to celebrate life sciences leaders
Pharma giants seek closure on COVID-19 vaccine rows
How Inhibrx defended a $450m damages suit
Foley & Lardner adds litigation and transaction expert in New York